Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.

Cells - 3 Jun 2020

Dao Trong Philip, Jungwirth Gerhard, Yu Tao, Pusch Stefan, Unterberg Andreas, Herold-Mende Christel, Warta Rolf

Abstract excerpt

The discovery of the isocitrate dehydrogenase (IDH) mutation in glioma led to a paradigm shift on how we see glioma biology. Difficulties in cultivating IDH mutant glioma stem cells (IDHmut GSCs) resulted in a paucity of preclinical models in IDHmut glioma, limiting the discovery of new effective chemotherapeutic agents. To fill this gap, we used six recently developed patient-derived IDHmut GSC lines and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Annexin A5
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Drug Screening Assays, Antitumor

Share to Inhibitory Concentration 50

Share to Isocitrate Dehydrogenase

Share to Neoplastic Stem Cells

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 32503220
DOI: 10.3390/cells9061389
PMCID: PMC7348988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.PMID 32503220Read ↗

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesSemantic proximity Read ↗

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell culturesSemantic proximity Read ↗

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsSemantic proximity Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

A Systematic Comparison Identifies an ATP‐Based Viability Assay as Most Suitable Read‐Out for Drug Screening in Glioma Stem‐Like CellsSemantic proximity Read ↗

From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.Semantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

IDH inhibition in gliomas: from preclinical models to clinical trialsSemantic proximity Read ↗

Novel IDH1-Targeted Glioma Therapies.Semantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Multi-omics and pharmacological characterization of patient-derived glioma cell linesSemantic proximity Read ↗

Non-oncology drugs are a source of previously unappreciated anti-cancer activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.